TY - JOUR
T1 - Dose-finding study on biapenem in complicated urinary tract infection
AU - Kawada, Yukimichi
AU - Deguchi, Takashi
AU - Aso, Yoshio
AU - Oshi, Masaya
AU - Kamidono, Sadao
AU - Arakawa, Soichi
AU - Ohmori, Hiroyuki
AU - Kumon, Hiromi
AU - Kumazawa, Joichi
AU - Matsumoto, Tetsuo
AU - Nakashima, Mitsuyoshi
AU - Kaku, Mitsuo
PY - 1994
Y1 - 1994
N2 - To find the optimal dose of biapenem (BIPM), a new parenteral carbapenem, in the treatment of complicated urinary tract infection, we performed a randomized, prospective, wellcontrolled study using imipenem/cilastatin (IPM/CS) as the control drug. The subjects had complicated urinary tract infection with pyuria of at least 5 WBCS/HPF, bacteriuria of at least 104CFU/ml and identifiable underlying urinary tract disease. Only hospitalized patients without indwelling catheters were enrolled in the study. Patients were randomly assigned to receive 150 mg b. i. d. of BIPM (group L), 300 mg b. i. d. of BIPM (group H) or 500 mg/500 mg b. i. d. of IPM/CS (group C) by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated on the basis of criteria proposed by the Japanese UTI Committee as “excellent”, “moderate” or “poor”. Excellent and moderate responses were obtained in 78.9% of 19 patients in group L, 84.6% of 26 patients in group H and 81.0% of 21 patients in group C. The differences were not statistically significant. The bacteriological eradication rates achieved were 91.3% of 23 strains in group L, 90.9% of 33 strains in group H and 93.3% of 30 strains in group C, with no statistically significant differences. Clinical adverse reactions were experienced in 4.2% of 24 patients in group L, none of 28 patients in group H and none of 24 patients in group C, with no statistically significant differences. Clinical value also was not significantly different among the three groups. From the results obtained in this study, we concluded that the optimal daily dose of BIPM in the treatment of complicated urinary tract infection is 300 mg b. i. d.
AB - To find the optimal dose of biapenem (BIPM), a new parenteral carbapenem, in the treatment of complicated urinary tract infection, we performed a randomized, prospective, wellcontrolled study using imipenem/cilastatin (IPM/CS) as the control drug. The subjects had complicated urinary tract infection with pyuria of at least 5 WBCS/HPF, bacteriuria of at least 104CFU/ml and identifiable underlying urinary tract disease. Only hospitalized patients without indwelling catheters were enrolled in the study. Patients were randomly assigned to receive 150 mg b. i. d. of BIPM (group L), 300 mg b. i. d. of BIPM (group H) or 500 mg/500 mg b. i. d. of IPM/CS (group C) by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated on the basis of criteria proposed by the Japanese UTI Committee as “excellent”, “moderate” or “poor”. Excellent and moderate responses were obtained in 78.9% of 19 patients in group L, 84.6% of 26 patients in group H and 81.0% of 21 patients in group C. The differences were not statistically significant. The bacteriological eradication rates achieved were 91.3% of 23 strains in group L, 90.9% of 33 strains in group H and 93.3% of 30 strains in group C, with no statistically significant differences. Clinical adverse reactions were experienced in 4.2% of 24 patients in group L, none of 28 patients in group H and none of 24 patients in group C, with no statistically significant differences. Clinical value also was not significantly different among the three groups. From the results obtained in this study, we concluded that the optimal daily dose of BIPM in the treatment of complicated urinary tract infection is 300 mg b. i. d.
KW - biapenem
KW - imipenem/cilastatin
UR - http://www.scopus.com/inward/record.url?scp=0027996030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027996030&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.42.1114
DO - 10.11250/chemotherapy1953.42.1114
M3 - Article
AN - SCOPUS:0027996030
VL - 42
SP - 1114
EP - 1127
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3165
IS - 10
ER -